Results 31 to 40 of about 17,718 (201)

Evaluation of the Response to Ranibizumab Therapy following Bevacizumab Treatment Failure in Eyes with Diabetic Macular Edema

Case Reports in Ophthalmology, 2015
Background/Aims: Bevacizumab and ranibizumab are routinely used to treat diabetic macular edema (DME). We aim to evaluate the usefulness of switching to ranibizumab therapy following bevacizumab treatment failure in eyes with DME. Methods: We performed a
Joel Hanhart, Itay Chowers
doaj   +1 more source

The Port Delivery System with ranibizumab: a new paradigm for long-acting retinal drug delivery

Drug Delivery, 2022
The Port Delivery System with ranibizumab (PDS) is an innovative intraocular drug delivery system designed for the continuous delivery of ranibizumab into the vitreous for 6 months and beyond.
Shrirang V. Ranade, Mark R. Wieland, Tammy Tam, Jennifer C. Rea, Judit Horvath, Aaron R. Hieb, Weitao Jia, Lori Grace, Giulio Barteselli, Jay M. Stewart   +9 more
doaj   +1 more source

Non‐invasive and efficient diabetic retinal mitochondrial repair nanoplatform based on engineered endothelial mitochondrial‐derived vesicles with dynamic integrated stress response modulation

Interdisciplinary Medicine, EarlyView.
Under hyperglycemic conditions, mitochondrial dysfunction in retinal endothelial cells triggers excessive reactive oxygen species/reactive nitrogen species production, barrier protein degradation, and endothelial barrier breakdown in diabetic retinopathy.
Siyu Gui, Jie Gao, Tianchang Tao, Peng Wang, Zhihao Huang, Yuyang She, Jiajie Li, Jingwan Su, Zhe Lu, Jianchao Qiao, Song Wang, Xiaodong Sun, Mohan Li   +12 more
wiley   +1 more source

Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment

BMJ Open Ophthalmology, 2023
Topic This systematic review and meta-analysis provides a summary of the efficacy and safety of ranibizumab biosimilars relative to reference ranibizumab anti-vascular endothelial growth factor (VEGF) therapy for the treatment of neovascular age-related ...
Netan Choudhry, Amin Hatamnejad, Rohan Dadak, Samantha Orr, Charles Wykoff   +4 more
doaj   +1 more source

Secretory autophagy and epithelial‐to‐mesenchymal transition in cadaveric AMD samples: Novel pathways in disease progression

Acta Ophthalmologica, EarlyView.
Abstract Purpose To examine the presence of secretory autophagy and epithelial–mesenchymal transition (EMT) in the macular retinal pigment epithelium (RPE) of human cadaver eyes with different forms of age‐related macular degeneration (AMD). Methods Human cadaver macula samples representing dry and wet AMD, as well as age‐matched controls, were ...
Iswariyaraja Sridevi Gurubaran, Ali Koskela, Hanna Heloterä, Kai Kaarniranta   +3 more
wiley   +1 more source

Comparison of three loading doses of bevacizumab and ranibizumab for macular edema due to branch retinal vein occlusion

BMC Ophthalmology
Objective To compare the effectiveness and safety of three loading doses of bevacizumab and ranibizumab for macular edema (ME) due to branch retinal vein occlusion (BRVO). Methods This retrospective study included 49 patients with BRVO. The patients were
Sibel Coşkun Akdemir, Nurdan Gamze Taşlı   +1 more
doaj   +1 more source

Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials

BMC Ophthalmology, 2018
Background To evaluate the relative efficacy and safety of anti-vascular endothelial growth factor (anti-VEGF) agents for the treatment of neovascular age-related macular degeneration (AMD). Methods Systematic literature review identifying RCTs comparing
Chu Luan Nguyen, Lawrence J. Oh, Eugene Wong, Joe Wei, Michael Chilov   +4 more
doaj   +1 more source

Comparison between intravitreal ranibizumab injection and posterior subtenon triamcinolone acetonide injection at time of cataract surgery for prevention of progression of diabetic macular edema

BMC Ophthalmology, 2022
Background The goal of this work is to assess progression of diabetic macular edema (DME) following intravitreal ranibizumab injection compared to subtenon triamcinolone acetonide injection at cataract operation. Methods Retrospective analysis of 73 eyes
Mahmoud Mohammed Ahmed Ali Khalil, Hosam Othman Mansour, Ahmed Mohamed Raafat Tawfik, Ahmed Gomaa Elmahdy   +3 more
doaj   +1 more source

Interventions for submacular haemorrhage: A systematic review and network meta‐analysis of controversies—On behalf of the Spanish Vitreo‐Retinal Society (SERV)

Acta Ophthalmologica, EarlyView.
Abstract Purpose This systematic review aims to evaluate and synthesize the existing literature on the interventions used for submacular haemorrhage (SMH), highlighting the controversies and differences in clinical practice. Method A systematic review was conducted following the PRISMA guidelines.
Salvador Pastor‐Idoate, Pablo Redruello‐Guerrero, Laura de Juan Hernández, Gregorio Benites‐Narcizo, Mario Rivera‐Izquierdo, José García‐Arumí, José Carlos Pastor Jimeno   +6 more
wiley   +1 more source

SD‐OCT‐based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti‐VEGF therapy

Acta Ophthalmologica, EarlyView.
Abstract Purpose To investigate the role of spectral domain optical coherence tomography (SD‐OCT)‐based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti‐vascular endothelial growth factor (VEGF) therapy.
Ken K. Tsang, Vivian W. K. Hui, Christopher M. K. Pang, Ziqi Tang, Dawei Yang, Truong X. Nguyen, Shaheeda Mohamed, Timothy Y. Y. Lai, Carol Y. Cheung, Simon K. H. Szeto   +9 more
wiley   +1 more source